Despite their utility, RECIST criteria have limitations. They primarily focus on changes in tumor size, which may not fully capture the biological activity of certain therapies, such as immunotherapies. These therapies can sometimes lead to initial tumor growth followed by shrinkage, a phenomenon not well-accounted for by traditional RECIST criteria. As a result, modified versions like iRECIST have been proposed to address these limitations.
